Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer.
CONCLUSION: In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials. Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk. Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.
PMID: 24127446 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Chavez-Macgregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH Tags: J Clin Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Clinical Trials | Congestive Heart Failure | Databases & Libraries | Heart | Heart Failure | Herceptin | Hypertension | Medicare | Statistics | Study